Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023
Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023
- SEC Filing
-美國證券交易委員會備案
On February 26, 2024, Ampio Pharmaceuticals, Inc. (the "Company") provided a notice to H.C. Wainwright & Co., LLC to terminate that certain At The Marketing Offering Agreement, dated September 18, 2023, by and between the Company and H.C. Wainwright & Co., LLC (the "ATM Agreement"), establishing an at-the-market equity distribution program for the offer and sale from time to time shares of the Company's common stock, par value $0.0001. In accordance with the ATM Agreement, the termination will be effective March 6, 2024.
2024年2月26日，Ampio Pharmicals, Inc.（以下簡稱 “公司”）向H.C. Wainwright & Co., LLC發出通知，要求終止公司與H.C. Wainwright & Co., LLC於2023年9月18日簽訂的某些營銷發行協議（“ATM協議”），該協議爲不時要約和出售公司股票制定了市場股權分配計劃的普通股，面值0.0001美元。根據自動櫃員機協議，終止將於2024年3月6日生效。
In connection with the termination of the ATM Agreement, the Company filed on February 28, 2024 a post-effective amendment to its Registration Statement on Form S-3 (File No. 333-274558) to withdraw and remove from registration any and all Company securities that remain unsold or otherwise unissued under such Registration Statement, including shares of the Company's common stock that were covered by the at-the-market offering agreement prospectus filed as part of the Registration Statement.
關於自動櫃員機協議的終止，公司於2024年2月28日提交了對S-3表格註冊聲明（文件編號333-274558）的生效後修正案，要求撤回和刪除根據該註冊聲明提交的所有未售出或未發行的公司證券，包括作爲註冊聲明一部分提交的上市發行協議招股說明書所涵蓋的公司普通股。
譯文內容由第三人軟體翻譯。